This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Olaratumab with doxorubicin for advanced soft tissue sarcoma. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015
Soft tissue sarcoma is a group of rare cancers that can occur in any part of the body. Sarcoma is usually treated with surgery, but the cancer often returns or spreads to other parts of the body.
Olaratumab is a new drug for the treatment of soft tissue sarcoma that can no longer be treated with surgery. It is delivered directly into the bloodstream through a drip. Some studies have suggested olaratumab may work best in combination with a chemotherapy drug already used for the treatment of this disease called doxorubicin.
If olaratumab is licensed for use in the UK, it could be a new treatment option for patients with advanced soft tissue sarcoma that may improve survival.
Subject indexing assigned by CRD
Antibodies, Monoclonal; Doxorubicin; Humans; Sarcoma
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: email@example.com
Date abstract record published